Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,732.00
(
-0.27%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
110.15
(
3.34%
)
Bitcoin
70,107.86
(
-1.59%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 193733

Thursday, 08/06/2015 10:12:31 AM

Thursday, August 06, 2015 10:12:31 AM

Post# of 257257
(MNTA)—MYL’s 2015 guidance excludes any contribution from generic Copaxone:

http://finance.yahoo.com/news/mylan-second-quarter-2015-constant-110000579.html

Previously, MYL had implicitly included Copaxone sales in 2015 guidance on a probability-adjusted basis, so today’s statement is change.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now